Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics

Pain, Intractable Clinical Trial

Official title:
An Open Label Study to Confirm the Effectiveness, and Safety of Fentanyl Transdermal Matrix Patch in Japanese Patients With Chronic Intractable Pain Who Has Prior Therapy of Codeine, Morphine Hydrochloride, or Fentanyl Injectable Preparations.

Status Completed

Clinical Trial Summary

The purpose of this study is to verify the effectiveness, and safety in Japanese patients with chronic intractable pain after 4-week medication of fentanyl transdermal matrix patches containing either 12.5 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, or 100 mcg/hr, who have been switched from existing formulations, such as codeine, morphine hydrochloride, or fentanyl injectable. Furthermore, the safety and effectiveness of long term treatment such as 48 weeks are to be assessed, if possible.

Clinical Trial Description

Fentanyl transdermal matrix patch is a narcotic analgesic agent. Compared with the existing reservoir-type Durotep® Patch, fentanyl transdermal matrix patch is not liable to leakage of drug solution and does not contain alcohol, which becomes a cause of skin irritation. Also this new formulation has become available in a smaller dose of 12.5mg/hr while the smallest Durotep® Patch is 25mg/hr. While Durotep® Patch is currently indicated only for cancer pain in Japan, this clinical trial was planned to assess effectiveness, and safety of fentanyl transdermal matrix patch in Japanese patients with chronic intractable pain receiving codeine, morphine hydrochloride, or fentanyl injectable formulations. After pre-treatment period for seven to fourteen days for evaluating the eligibility of the patients for the study, patients will be treated for 4 weeks as Treatment period 1 and 48 weeks as Treatment period 2 followed by 3-day post-treatment observation period. One patch can be used for 72 hours, which is the same as the existing Patch. Starting from the first day of treatment, fentanyl will be applied to the chest, the upper arm or other appropriate site, which will be replaced with a new patch every three days (ca. 72 hr). Starting dose should be between 12.5 mcg/hr and 75 mcg/hr, depending on the prior opioid dose. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Pain, Intractable

Clinical Trial Details

NCT number	NCT00216684
Study type	Interventional
Source	Janssen Pharmaceutical K.K.
Contact
Status	Completed
Phase	Phase 3
Start date	May 2005
Completion date	September 2006

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03887494` - Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY)	N/A
Recruiting	`NCT05761392` - APP-based Precise Management System of Chronic Intractable Pain	N/A
Suspended	`NCT05067257` - Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer	Phase 2
Enrolling by invitation	`NCT02485795` - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management	N/A
Withdrawn	`NCT01951911` - Effectiveness of Ketamine in Malignant Neuropathic Pain Relief	Phase 3
Completed	`NCT04701008` - Efficacy of Ketamine in Post Anesthesia Recovery Room
Completed	`NCT03350256` - BurstDR™ micrOdosing stimuLation in De-novo Patients	N/A
Completed	`NCT04602286` - How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample)	N/A
Completed	`NCT04625504` - Investigating Biological Targets, Markers, and Intervention for Chronic Pain	N/A
Recruiting	`NCT05398003` - Medullary Stimulation for the Treatment of Refractory Neck Pain (S2M)	N/A
Completed	`NCT02886286` - Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain	Phase 4
Recruiting	`NCT05775510` - Study to Evaluate Neuromodulation Subject Experience With Contemporary Spinal Cord Stimulation (SCS) Modalities for Chronic Pain
Active, not recruiting	`NCT04727216` - Intermittent vs. Continuous Dorsal Root Ganglion Stimulation	N/A
Completed	`NCT02091076` - Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing	Phase 1/Phase 2
Completed	`NCT01166906` - Pain Blocking During Drug Administration or Blood Collection With Needles
Recruiting	`NCT04876469` - Radiocontrast Media in the Pulsed Radiofrequency Treatment	N/A
Completed	`NCT05108103` - Determination of Longus Colli Muscle Thickness by Ultrasonography
Completed	`NCT04727749` - Pawsitive Impacts of Therapy Dog Visits	N/A
Completed	`NCT04096391` - Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population	N/A
Terminated	`NCT00122915` - CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.